drugset / Trial / NCT01699347

Cohort Prospective Study of Children With Head and Neck Cystic Malformation Who Are Treated With Intracystic OK432

NCT01699347

Phase 4 Unknown 5 enrolled Carmel Medical Center
NaSingle-groupOpen-labelTreatment

Summary

Cohort study evaluate the efficacy treatment with OK-432 in cystic malformation of the head and neck region. The malformations are macrocystic and the preevaluation will include CT/MRI, US and blood tests. The injection will be in the OR under US guided, maximal dose will be 0.2mg. The follow-up will be of short term - till 30 days post injection and long term - follow-up wil be till 2 years.

Timeline

Start
2012-09
Primary completion
2014-01
Completion
2016-01

Drugs

EvaluationDrugModalityDoseRoute
Subject OK-432 Unknown 0.2 mg Other

Indications

No indication recorded.